Business Development
Mitochondria are factories of energy that generate ATP and sustain life. Less is known about their role as a signaling apparatus that promote health and induce cell death when necessary. Damage to mitochondria leads to loss of energy, accumulation of misfolded proteins and aggregates that in turn de-polarize mitochondria and further loss of ATP and ultimately cell death. Due to high metabolic demand, neurons and especially dopaminergic regions of the brain are especially susceptible to mitochondrial damage. Gradual decline in neuronal function takes place beyond age 40 years, if mitochondrial damage is not repaired the aging process exacerbates. Insomnia, memory loss, cognition and neurodegeneration are signs of poor mitochondrial function in the brain. The role of healthy mitochondria is vital to prevent neurodegeneration. Myto Health nutraceuticals and small molecules are studied by many labs around USA to establish it role in preventing Alzheimer’s and Parkinson’s disease (AD and PD) models. Mitochondria is also a lifeline for muscle function. To that end its role in the heart and skeletal muscle is critical. At Myto Health we are working to validate small molecules that prevent heart attacks and promote rapid recovery from ischemia in animal models. High lipid load in obesity damages mitochondria, healthy mitochondria metabolize lipid content, reduces reactive oxygen, and promotes healthy aging. Thus, the role of healthy mitochondria is bedrock for good health and healthy aging.
Myto Health Business Model
Myto Health technology engine is driven by collection of tools to discover drugs and nutraceuticals and blood-based diagnostic biomarkers for aging and neurodegeneration by interrogating ubiquitin pathway enzymes such as ubiquitin ligases. Poly-ubiquitination of proteins is a code that is not completely understood. For example, building lysine 6 linked chain on mitochondrial proteins initiates mitophagy. Building of K63 poly-ubiquitin chains initiates autophagy, building lysine 48 linked poly-ubiquitin chains removes misfolded or aggregated proteins by proteasome and so on. Myto Health has developed numerous assays for ligases and poly-ubiquitin chains selective affinity matrices to address multiple areas and develop blood-based diagnostic biomarkers. Myto Health screened natural products libraries against ubiquitin ligases to discover nutraceuticals. Rationale designs of small molecules have helped discover E3 ligase(s) activators that promote mitophagy and mitobiogenesis. We believe these molecules have multi-indication properties. The blood-based diagnostic signatures of poly-ubiquitins will have broad diagnostic applications for early detection of Parkinson’s disease as well as other aging markers. Because of the breadth and depth of the platform translation of these products and services into clinic requires highly accomplished teams. Myto Health plans to share, partner, establish joint ventures, license, and seek investments to bring these technologies to patients and consumers. Myto Health invites inquiries from collaborators, investors, and organizations to explore these technologies to bring to market pace and ultimately benefit the patients. We are particularly interested in sharing the following technologies:
- Blood-based ubiquitin signature for diagnosis of Parkinson’s disease
- Nutraceuticals that promote mitophagy and mitobiogenesis.
- Rational designed small molecule to activate mitophagy and mitobiogenesis.
Please connect with [email protected]
Contact: Sarah Thomas
Business Development Manager
Myto Health LLC
[email protected]
www.mytohealth.net
Phone: (610) 644-6974 EXT 301